Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer

 Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer

Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer

Shots:

  • The P-III MONARCH 2 study involves assessing of Verzenio + fulvestrant vs PBO + fulvestrant in 669 pre/peri- and postmenopausal women in a ratio (2:1) with HR+, HER2- metastatic breast cancer whose cancer progressed following endocrine therapy
  • The P-III MONARCH 2 study resulted in meetings 2EP of overall survival with no new observed safety signals. The P-III MONARCH study previously met its 1EPs i.e, improvement in PFS which serves as the basis for its approval in 50+ countries
  • Verzenio is a CDK 4 & 6 inhibitors which are activated by binding to D-cyclins, inhibiting Rb phosphorylation with blocking progression from G1 to S phase of the cell cycle resulting in senescence and apoptosis

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: NICE

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post